CPRX vs NDAQ · P/E 18, rev $491.7M vs P/E 41, rev $2.53B
Catalyst Pharmaceuticals Inc (CPRX) versus Nasdaq Inc (NDAQ) — a side-by-side from cached financials, not a winner call.
Catalyst Pharmaceuticals Inc (CPRX) is a biotechnology company listed on NASDAQ.
Nasdaq Inc (NDAQ) is a financial data & stock exchanges company listed on US.
Latest reported CPRX revenue for 2024-12-31 was $491.7M. Net income was $163.9M. Revenue was up 23.5% from 2023-12-31 to 2024-12-31. CPRX currently screens at market cap $3.84B and trailing P/E 18.2.
Latest reported NDAQ revenue for 2026-06-30 was $2.53B. Net income was $507.0M. Revenue was up 18.5% from 2026-03-31 to 2026-06-30. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
CPRX currently screens at market cap $3.84B and trailing P/E 18.2. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
Not investment advice. Open the CPRX and NDAQ stock pages for the full models.
Not investment advice.